NanoHybrids

NanoHybrids develops nanotechnology-based solutions—primarily gold nanoparticle contrast agents—for enhanced non-invasive biomedical imaging, molecular profiling, and theranostic applications. Their proprietary technologies enable high-resolution tumor visualization, targeted hyperthermia treatments in partnership with Siva Therapeutics, and improved photodynamic therapies. The company has received NIH/NCI funding to advance its platforms toward clinical use but remains primarily at the preclinical/early development stage. Products such as PAtrace are marketed for research use to measure the EPR effect in tumors. Distribution partnerships exist with companies like Eikonix for broader market reach.